Literature DB >> 20721784

Statistical inference for tumor growth inhibition T/C ratio.

Jianrong Wu1.   

Abstract

The tumor growth inhibition T/C ratio is commonly used to quantify treatment effects in drug screening tumor xenograft experiments. The T/C ratio is converted to an antitumor activity rating using an arbitrary cutoff point and often without any formal statistical inference. Here, we applied a nonparametric bootstrap method and a small sample likelihood ratio statistic to make a statistical inference of the T/C ratio, including both hypothesis testing and a confidence interval estimate. Furthermore, sample size and power are also discussed for statistical design of tumor xenograft experiments. Tumor xenograft data from an actual experiment were analyzed to illustrate the application.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721784      PMCID: PMC4668933          DOI: 10.1080/10543401003618983

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  11 in total

1.  The pediatric preclinical testing program: description of models and early testing results.

Authors:  Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

2.  Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

Authors:  J Thompson; E O George; C A Poquette; P J Cheshire; L B Richmond; S S de Graaf; M Ma; C F Stewart; P J Houghton
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

3.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

Authors:  M C Bissery; D Guénard; F Guéritte-Voegelein; F Lavelle
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

4.  Statistical analysis of in vivo tumor growth experiments.

Authors:  D F Heitjan; A Manni; R J Santen
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

5.  Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.

Authors:  Thomas H Corbett; Kathryn White; Lisa Polin; Juiwanna Kushner; Jennifer Paluch; Chuan Shih; Cora Sue Grossman
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

Review 6.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.

Authors:  Theodora Voskoglou-Nomikos; Joseph L Pater; Lesley Seymour
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

7.  Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.

Authors:  Ming Tan; Hong-Bin Fang; Guo-Liang Tian; Peter J Houghton
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

8.  Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.

Authors:  Peter Atadja; Lin Gao; Paul Kwon; Nancy Trogani; Heather Walker; Meier Hsu; Lakshmi Yeleswarapu; Nagarajan Chandramouli; Larry Perez; Richard Versace; Arthur Wu; Lidia Sambucetti; Peter Lassota; Dalia Cohen; Kenneth Bair; Alexander Wood; Stacy Remiszewski
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

9.  Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

Authors:  E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Richard Lock; Hernan Carol; C Patrick Reynolds; John M Maris; Stephen T Keir; Catherine A Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2008-06       Impact factor: 3.167

10.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

View more
  9 in total

1.  The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.

Authors:  Nehad M Ayoub; Abu Bakar Siddique; Hassan Y Ebrahim; Mohamed M Mohyeldin; Khalid A El Sayed
Journal:  Eur J Pharmacol       Date:  2017-06-15       Impact factor: 4.432

2.  ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies.

Authors:  Melinda G Hollingshead; Nathaniel Greenberg; Michelle Gottholm-Ahalt; Richard Camalier; Barry C Johnson; Jerry M Collins; James H Doroshow
Journal:  Cancer Res       Date:  2022-06-15       Impact factor: 13.312

3.  Untangling the model muddle: Empirical tumour growth in Tasmanian devil facial tumour disease.

Authors:  Rodrigo K Hamede; Nicholas J Beeton; Scott Carver; Menna E Jones
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 4.  Recent Developments of Supramolecular Metal-based Structures for Applications in Cancer Therapy and Imaging.

Authors:  Alexander Pöthig; Angela Casini
Journal:  Theranostics       Date:  2019-05-18       Impact factor: 11.556

5.  EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.

Authors:  Anna Rommer; Birgit Steinmetz; Friederike Herbst; Hubert Hackl; Petra Heffeter; Daniela Heilos; Martin Filipits; Katarina Steinleitner; Shayda Hemmati; Irene Herbacek; Ilse Schwarzinger; Katharina Hartl; Pieter Rondou; Hanno Glimm; Kadin Karakaya; Alwin Krämer; Walter Berger; Rotraud Wieser
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

6.  Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.

Authors:  Claudia Weidensteiner; Peter R Allegrini; Melanie Sticker-Jantscheff; Vincent Romanet; Stephane Ferretti; Paul M J McSheehy
Journal:  BMC Cancer       Date:  2014-02-14       Impact factor: 4.430

7.  Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.

Authors:  U Harjes; E Bridges; K M Gharpure; I Roxanis; H Sheldon; F Miranda; L S Mangala; S Pradeep; G Lopez-Berestein; A Ahmed; B Fielding; A K Sood; A L Harris
Journal:  Oncogene       Date:  2016-08-29       Impact factor: 9.867

8.  Efficacy of osimertinib against EGFRvIII+ glioblastoma.

Authors:  Gustavo Chagoya; Shawn G Kwatra; Cory W Nanni; Callie M Roberts; Samantha M Phillips; Sarah Nullmeyergh; Samuel P Gilmore; Ivan Spasojevic; David L Corcoran; Christopher C Young; Karla V Ballman; Rohan Ramakrishna; Darren A Cross; James M Markert; Michael Lim; Mark R Gilbert; Glenn J Lesser; Madan M Kwatra
Journal:  Oncotarget       Date:  2020-06-02

9.  Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.

Authors:  Crescenzo D'Alterio; Maria Buoncervello; Caterina Ieranò; Maria Napolitano; Luigi Portella; Giuseppina Rea; Antonio Barbieri; Antonio Luciano; Giosuè Scognamiglio; Fabiana Tatangelo; Anna Maria Anniciello; Mario Monaco; Ernesta Cavalcanti; Piera Maiolino; Giulia Romagnoli; Claudio Arra; Gerardo Botti; Lucia Gabriele; Stefania Scala
Journal:  J Exp Clin Cancer Res       Date:  2019-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.